Physician profile
Herman D Lu
NPI 1073596912
$24,090.41
in general payments reported to CMS, 2019-2025
42 companies · $1,959 in 2025
The $1,959 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,803 · 2020: $4,489 · 2021: $4,161 · 2022: $2,792 · 2023: $3,508 · 2024: $2,378 · 2025: $1,959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,505 · Travel and Lodging: $1,181 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,504.65 |
| Travel and Lodging | $1,181.13 |
| Education | $159.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,609.85 | 2019-2025 | Farxiga, Lokelma |
| Abbott Laboratories | $3,088.70 | 2019-2025 | Jot Dx, Aveir, Mitraclip |
| Novartis Pharmaceuticals Corporation | $2,254.94 | 2019-2025 | |
| Medtronic, INC. | $2,008.55 | 2021-2025 | Linq II, Symplicity G3, Corevalve Evolut R |
| Amgen INC. | $1,225.77 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $1,183.41 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,031.59 | 2019-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $956.60 | 2019-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $864.89 | 2020-2025 | Nexletol |
| Novo Nordisk INC | $677.29 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $478.66 | 2020-2025 | Jardiance |
| Siemens Medical Solutions USA, INC. | $415.99 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $347.79 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Merck Sharp & Dohme LLC | $341.77 | 2022-2025 | Verquvo |
| Amarin Pharma, INC. | $292.08 | 2019-2022 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $284.43 | 2022-2024 | Optimizer, Optimizer |
| Kiniksa Pharmaceuticals International, Plc | $267.46 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $222.99 | 2019-2023 | |
| Janssen Scientific Affairs, LLC | $209.73 | 2021-2022 | |
| Pfizer INC. | $195.73 | 2019-2025 | |
| Chiesi USA, INC. | $186.88 | 2023-2025 | Kengreal, Cleviprex |
| Philips North America LLC | $175.36 | 2022 | |
| Medtronic Vascular, INC. | $174.45 | 2020 | |
| Inari Medical, INC. | $149.99 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $146.90 | 2019-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $144.04 | 2021-2023 | Arcalyst |
| Penumbra, INC. | $137.48 | 2025 | Indigo System |
| Silk Road Medical, INC. | $132.75 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Ethicon US, LLC | $124.51 | 2019 | |
| Boston Scientific Corporation | $116.40 | 2022-2024 | Eluvia |
| Cathworks, INC. | $96.23 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $89.51 | 2019-2025 | Evkeeza |
| Edwards Lifesciences Corporation | $78.99 | 2020-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Cvrx, INC. | $78.95 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $72.38 | 2025 | Amvuttra |
| Ionis Pharmaceuticals, INC. | $59.90 | 2025 | Tryngolza |
| Heartflow, INC. | $53.66 | 2022 | |
| Inspire Medical Systems, INC. | $34.04 | 2023-2025 | Inspire |
| Lexicon Pharmaceuticals, INC. | $26.26 | 2024 | |
| Cleerly, INC. | $20.41 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Arbor Pharmaceuticals, INC. | $18.27 | 2021 | |
| Abiomed | $14.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herman Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.